https://www.avient.com/sites/default/files/2021-03/avient-antitrust-2021-update-de-a4.pdf
https://www.avient.com/sites/default/files/2022-05/Avient_Health_And_Safety_Policy_2022 Update.pdf
https://www.avient.com/sites/default/files/2025-02/Avient Investor Presentation - February 2025_w_Non-GAAP.pdf
Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: • disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; • the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; • disruptions or inefficiencies in our supply chain, logistics, or operations; • changes in laws and regulations in jurisdictions where we conduct business, including with respect to plastics and climate change; • fluctuations in raw material prices, quality and supply, and in energy prices and supply; • demand for our products and services; • production outages or material costs associated with scheduled or unscheduled maintenance programs; • unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; • our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; • information systems failures and cyberattacks; • our ability to service our indebtedness and restrictions on our current and future operations due to our indebtedness; • amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions; • other factors affecting our business beyond our control, including without limitation, changes in the general economy, changes in interest rates, changes in the rate of inflation, geopolitical conflicts, and any recessionary conditions; and • other factors described in our Annual Report on Form 10-K under Item 1A, “Risk Factors.”
Any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
EPS guidance 2025 financial guidance ▲ Further Fed rate cuts ▲ Chinese stimulus ▲ Economic recovery in Europe ▲ Continued strength in defense applications for both military and local law enforcement ▼ Policy uncertainty and changes ▼ Persistent inflation impacting consumer spending / slowdown of US economy ▼ Further deterioration of Europe economy ▼ FX volatility MACRO ASSUMPTIONS INFLUENCING RANGE 23Copyright © .
https://www.avient.com/sites/default/files/2021-10/avnt-q3-2021-news-release.pdf
We are excited to lay out our long-term growth plans, highlighting our sustainable solutions portfolio as well as provide an update on the synergies expected from the Clariant color business acquisition,” said Jamie Beggs, Senior Vice President and Chief Financial Officer, Avient Corporation.
Factors that could cause actual results to differ materially from those implied by these forward-looking statements include disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; the current and potential future impact of the COVID-19 pandemic on our business, results of operations, financial position or cash flows including without any limitation, any supply chain and logistics issues; our ability to achieve the strategic and other objectives relating to the acquisition of Clariant's Color business, including any expected synergies; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve the anticipated financial benefit from initiatives related to acquisition and integration working capital reductions, cost reductions and employee productivity goals; our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; information systems failures and cyberattacks; our ability to consummate and successfully integrate acquisitions; and amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions.
We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
https://www.avient.com/news/pharmapack-2025-feature-polymer-colorants-and-additives-avient-enhance-performance-and-sustainability
This portfolio combines expertise in polymer formulation with controlled manufacturing conditions and robust change control management beyond the Chemical Abstracts Service (CAS) identification number.
The materials are produced under a third-party certified ISO 13485:2016 quality management system and backed by comprehensive change control of raw materials, formulation, and manufacturing standards to enable consistent batch-to-batch quality.”
In doing so, we innovate solutions that help our customers overcome their challenges or capitalize on opportunities provided by the fast-changing world and secular trends.
https://www.avient.com/news/avient-site-taiwan-earns-iso-13485-accreditation-fourth-source-mevopur-medical-grade-materials
Say-Eng Lee, vice president and general manager, Color & Additives Asia says, “China and other Asian countries not only have a rapidly growing domestic healthcare market, but they are also actively supporting Western countries for medical product manufacturing, where they need to meet strict medical- and pharma-related standards for testing, traceability, and change control of the materials used in their products.
These are supported by laboratory facilities as well as technical and commercial teams that are thoroughly trained in risk assessment and change management, according to global MEVOPUR standards.
The goal behind the MEVOPUR concept is to help customers navigate more easily through a changing regulatory landscape,” explains Volker Dickfeld, global marketing manager Healthcare.
https://www.avient.com/news/colorforward-forecasts-focus-mid-tone-colors-2025
There is an underlying feeling of resiliency and pursuit of endurance that can inspire people to face large-scale changes, challenges, and crises with a positive attitude.”
The ELEVENS trend pronounces large-scale changes in several areas, from demographics and global economies to consumer power and quality of life for everyone.
The name was chosen because the number 11 is symbolically linked to transformation and changes.
https://www.avient.com/knowledge-base/article/strategies-manage-your-carbon-footprint
By implementing various strategies, you can reduce your carbon footprint and potentially mitigate the effects of climate change.
Globally, as of September 2023, almost 3,400 companies have set science-based goals – with 2,400 of those being net-zero commitments – in order to address greenhouse gas emission concerns (Science Based Targets).
Evaluating the carbon footprint within your industry’s value chain can help mitigate climate change – and can help meet certain sustainability goals.
https://www.avient.com/sites/default/files/2025-01/Securities Trading Policy %282024%29 Final.pdf
In order to ensure compliance with the policy, the Board of Directors of the Company has adopted the following additional procedures, which apply to (a) directors, officers and certain employees and representatives of the Company and of its affiliates, as specified in Annex A (“Covered Employees”), and (b) members of their immediate families, partnerships in which Covered Employees are a general partner; corporations in which Covered Employees, either singly or together with other Related Persons (as defined below), own a controlling interest; trusts of which Covered Employees are a trustee, settlor or beneficiary; estates of which Covered Employees are an executor or beneficiary; or any other group or entity where Covered Employees have or share with others the power to decide whether to buy Company securities (collectively, “Related Persons”).
The General Counsel maintains guidelines that all plans must meet in order to be considered for approval.
Sanders By Phone: (440) 930-1318 or By E-Mail: Amy.Sanders@Avient.com Jamie Beggs By Phone: (440) 930-3574 or By E-Mail: Jamie.Beggs@Avient.com mailto:Amy.Sanders@Avient.com mailto:Jamie.Beggs@Avient.com Revised: December 20, 2024 ANNEX C The following list illustrates examples of types of information that may be considered Inside Information, if not yet available to the public: Ø Unpublished monthly, quarterly or annual financial information, statements or reports for the Company or its subsidiaries; Ø Proposed mergers, acquisitions and divestitures; Ø Proposed new security issues; Ø Liquidity or cash problems; Ø Changes in earnings, dividends or other financial information; Ø Pending patents or new products; Ø Credit history; Ø Information concerning significant changes in the business or personal lives of senior-level management; Ø The existence of and risks associated with significant threatened or pending litigation; Ø Significant regulatory proceedings and governmental investigations involving the Company; Ø Significant cybersecurity incidents involving the Company; and Ø Awareness that the Company or management’s expectations regarding Company performance differ significantly from analysts’ expectations.
https://www.avient.com/sites/default/files/resources/Polyone%2520AR.pdf
We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.
Our contracts, generally in the form of purchase orders or written contracts, specify the product or service that is promised to the customer.
We are exposed to foreign currency changes and to changes in cash flows due to changes in our contractually specified interest rates (e.g, LIBOR) in the normal course of business.